Geneuro
Developing antibody therapies targeting pathogenic HERVs for MS and post-COVID syndromes.
GEM | PA
Overview
Corporate Details
- ISIN(s):
- CH0308403085
- LEI:
- 213800FUJCKXO9LK3444
- Country:
- Switzerland
- Address:
- chemin du Pré-Fleuri 3, 1228 Plan-les-Ouates
- Website:
- https://geneuro.ch/en/
- Sector:
- Professional, scientific and technical activities
- Industry:
- Research and experimental development on natural sciences and engineering
Description
GeNeuro is a clinical-stage biotechnology company that develops treatments for neurodegenerative and autoimmune diseases. The company's novel therapeutic approach focuses on neutralizing pathogenic proteins encoded by human endogenous retroviruses (HERVs), which are suspected of contributing to the onset and progression of various conditions. Its pipeline targets diseases such as multiple sclerosis (MS) and long-term neuropsychiatric syndromes observed in post-COVID patients. GeNeuro's primary drug candidate, timelimab, is a monoclonal antibody developed to target a specific pathogenic HERV protein, aiming to stop disease progression by addressing its root cause.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| 2025-09-26 18:36 |
Legal Proceedings Report
Inside Information / Other news releases
|
English | 212.6 KB | ||
| 2025-09-26 18:36 |
Legal Proceedings Report
Informations privilégiées / Autres communiqués
|
French | 215.2 KB | ||
| 2025-06-30 19:37 |
AGM Information
Inside Information / Other news releases
|
English | 224.5 KB | ||
| 2025-06-30 19:37 |
AGM Information
Informations privilégiées / Autres communiqués
|
French | 753.1 KB | ||
| 2025-06-12 22:42 |
Legal Proceedings Report
Inside Information / Other news releases
|
English | 204.9 KB | ||
| 2025-06-12 22:42 |
Legal Proceedings Report
Informations privilégiées / Autres communiqués
|
French | 203.8 KB | ||
| 2025-06-10 18:24 |
Legal Proceedings Report
Informations privilégiées / Autres communiqués
|
French | 207.4 KB | ||
| 2025-06-10 18:24 |
Pre-Annual General Meeting Information
Inside Information / Other news releases
|
English | 209.5 KB | ||
| 2025-05-27 18:00 |
Legal Proceedings Report
Inside Information / Other news releases
|
English | 162.5 KB | ||
| 2025-05-27 18:00 |
Legal Proceedings Report
Informations privilégiées / Autres communiqués
|
French | 187.1 KB | ||
| 2025-05-12 18:36 |
Report Publication Announcement
Inside Information / Other news releases
|
English | 481.8 KB | ||
| 2025-05-12 18:36 |
Report Publication Announcement
Informations privilégiées / Autres communiqués
|
French | 669.5 KB |
Automate Your Workflow. Get a real-time feed of all Geneuro filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for Geneuro
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for Geneuro via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
Peer Companies
